SYDNEY--(BUSINESS WIRE)--Innate Immunotherapeutics Limited (ASX Code: IIL), together with a number of Australian, Canadian, and Danish scientific collaborators, has had multiple abstracts accepted for presentation at the American Academy of Neurologists (AAN) Annual Meeting being held in Boston in late April.
The AAN Annual Meeting is the world's largest gathering of neurologists, bringing together more than 10,000 neurology professionals across the globe to network, discuss cutting-edge research, and take part in top-rated education programming across a wide variety of topics.
The titles of the six abstracts submitted to AAN, all of which were accepted, are listed below together with details of the key contributors. Innate director and co-founder of Receptos Inc (NASDAQ:RCPT), Robert Peach commented, “It's highly significant that the Company has had this number of abstracts accepted at AAN and it indicates strong scientific interest in Innate’s understanding of the MIS416 mechanism of action."
The data from this collective substantial body of work provides solid support for the proposed mechanism of action of MIS416, the Company's drug candidate currently in clinical trial for patients with secondary progressive multiple sclerosis (SPMS). The data to be presented demonstrate that MIS416 effectively engages two distinct and complementary signalling pathways which are master controllers of immune system homeostasis or 'balance'.
Innate's Chief Scientific Officer, Gill Webster says "the data importantly identify that engagement of both these pathways is central to the MIS416 treatment effect in neuroinflammation which is a unique feature of MIS416 compared to other immune modulators previously trialled in progressive multiple sclerosis."
Whereas five of the six abstracts focus on mechanism of action related research, one abstract reviews clinical data collected during the Company's earlier and smaller Phase 2A study of MIS416 in patients with SPMS. The lead author of this paper, Professor Nancy Mayo (McGill University, Montreal) concludes that data from the open label three month study indicate MIS416 therapy leads to improvement in patient's MS related clinical status.
The accepted abstracts are entitled:
Kynurenine pathway profiling in phase 2A trial secondary progressive
multiple Sclerosis patients treated with a myeloid directed innate
immune modulator MIS416
Chai Lim1, Gill Webster, Erin Lynch1, Hongyan An and Gilles Guillemin1 (1 Macquarie University, Sydney, Australia)
Evaluation of neurological improvements in secondary progressive
multiple sclerosis patients treated with myeloid targeted immune
Nancy E Mayo1 and Gill A Webster (1 Department of Medicine, McGill University, Montreal, Canada)
MIS416, a myeloid targeted immune modulator for the treatment of
secondary progressive multiple sclerosis acts directly within the CNS to
induce Type I IFN and suppress neuroinflammation
Reza Khorooshi1, Vian Wais1, Gill Webster and Trevor Owens1 (1 Neurobiology, Institute of Molecular Medicine, University of Southern Denmark)
Neuroprotective/Neuroreparative activity of MIS416, a
myeloid-directed innate immune therapeutic in Phase 2B trial for the
treatment of secondary progressive multiple sclerosis
Rebecca Girvan1, Victoria Pearson1, Massoud Hassanpour2 and Gill Webster1 (2 Innate Immunotherapeutics, 2 St Vincent’s Centre For Applied Medical Research, University Of New South Wales)
Modulation of post-traumatic epilepsy by MIS416, a novel innate
immune modulator for the treatment of neuroinflammation
Min Chen1, Vy Truong1, David C. Reutens1 and Gill Webster (1 Centre for Advanced Imaging, The University of Queensland)